R&D channel feed

#AACR20: Io­vance rev­els in promis­ing lung can­cer da­ta out of Mof­fitt as TIL ther­a­py trig­gers 2 com­plete re­spons­es

6 years ago

Eli Lil­ly ex­ecs have been think­ing about the longterm ef­fects of the pan­dem­ic and dam­age con­trol. Here’s what they be­lieve

6 years ago
People
Coronavirus

GSK flash­es pos­i­tive da­ta for Tesaro drug that could be­come 7th ap­proved PD-(L)1

6 years ago

Lyn­parza im­proves sur­vival rate in prostate can­cer, giv­ing As­traZeneca and Mer­ck an­oth­er win on PARP front

6 years ago

A slice of half-baked remde­sivir da­ta takes a dark turn — but we're still wait­ing for a de­fin­i­tive study

6 years ago
Bioregnum
Coronavirus

Piv­otal da­ta ce­ment use of In­cyte, No­var­tis' rux­oli­tinib in dif­fi­cult-to-treat graft-ver­sus-host dis­ease

6 years ago
Pharma

Bain helps push Affini­vax to next stage with $120M round, as PhII da­ta loom on a lead ef­fort to do some­thing new in vac­cines

6 years ago
Financing

Sanofi steps up with its da­ta on a new MS drug, shin­ing a spot­light on PhI­II hopes af­ter fend­ing off a short at­tack

6 years ago

Analy­sis shows Swiss biotech in­dex out­shines Nas­daq coun­ter­part, but coro­n­avirus chal­lenges are uni­ver­sal

6 years ago
Financing
Pharma

‘Break­through’ drugs in­clud­ed on Roche’s list of PhII/III stud­ies axed in Q1 — with piv­otal Mir­ros tri­al on the chop­ping block

6 years ago

First NDA in. Re­gion­al deal done. Now My­ovant has PhI­II da­ta to back up re­l­u­golix's push to an­oth­er block­buster mar­ket

6 years ago

Bio­gen push­es back its time­line on the big ad­u­canum­ab FDA fil­ing as Covid-19 slows work — shares wilt

6 years ago

Ab­b­Vie, J&J block­buster Im­bru­vi­ca rakes in 11th FDA ap­proval, as com­peti­tors work on erod­ing fran­chise

6 years ago
Pharma
FDA+

VA study spot­lights high­er death rate among Covid-19 pa­tients treat­ed with the con­tro­ver­sial drug hy­drox­y­chloro­quine

6 years ago
Coronavirus

More pos­i­tive PhI­II da­ta set stage for Scynex­is' vagi­nal yeast in­fec­tion drug ap­proval

6 years ago

Short at­tack tar­gets one of the fa­vorites now shar­ing the lead in the pop­u­lar KRAS drug de­vel­op­ment race

6 years ago

Data­vant boots up a big Covid-19 reg­istry — look­ing to shine a light on virus spread, im­pact and most ef­fec­tive ther­a­pies

6 years ago
Coronavirus

An­oth­er PhI­II win in hand, Cara aims straight for pri­or­i­ty re­view of 'break­through' pru­ri­tus drug

6 years ago

Piv­otal da­ta sug­gest clean safe­ty pro­file, po­ten­cy could set Idor­si­a's sleep­ing pill apart

6 years ago

Ex­elix­is lands PhI­II kid­ney can­cer win with Bris­tol My­ers in their hunt for $4 bil­lion

6 years ago

NIH cor­rals bio­phar­ma com­pa­nies, reg­u­la­tors and tri­al net­works to co­or­di­nate Covid-19 R&D

6 years ago
Coronavirus

Re­port on one PhI­II remde­sivir study sends in­vestors in­to over­drive, adding bil­lions to Gilead­'s mar­ket cap

6 years ago
Coronavirus

In­ter­im da­ta on Vir's Al­ny­lam-part­nered RNAi hep B drug sug­gest ef­fi­ca­cy is broad­ly on par with J&J, Ar­row­head ri­val — an­a­lysts

6 years ago

Abun­dant fund­ing, sparse da­ta: San Fran­cis­co start­up backs 're­al world' mod­el for rare dis­ease drug de­vel­op­ment

6 years ago
Financing
Startups
First page Previous page 204205206207208209210 Next page Last page
A service from the Financial Times